Login to Your Account

AACR 2014

Palbociclib shows PFS but not (yet?) OS benefit in phase II

By Anette Breindl
Science Editor

Monday, April 7, 2014
SAN DIEGO – Results presented at the of the American Association for Cancer Research (AACR) annual meeting on Sunday from the phase II PALOMA-1 trial of CDK inhibitor palbociclib (Pfizer Inc.) led to plenty of buzz that Pfizer Inc. might file for accelerated approval for the drug, despite the lack of an overall survival (OS) benefit to date. Researchers reported at the plenary session that treatment with the palbociclib doubled progression-free survival of women with metastatic estrogen receptor-positive (ER+) breast cancer in an open-label phase II trial when the drug was added to the standard treatment with the estrogen synthesis inhibitor letrozole.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription